Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The companies aim to expand treatment options for millions living with metabolic disorders
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Subscribe To Our Newsletter & Stay Updated